Commercialising neurofutures: Promissory economies, value creation and the making of a new industry

被引:32
作者
Martin, Paul [1 ]
机构
[1] Univ Sheffield, Dept Sociol Studies, Elmfield Bldg,Northumberland Rd, Sheffield S10 2TU, S Yorkshire, England
关键词
neuroscience; neurotechnology; expectations; promissory organisations; value; bioeconomy; VENTURE CAPITALISTS; GENE-THERAPY; EXPECTATIONS; TECHNOLOGY; FUTURES; TRUTH; HOPE;
D O I
10.1057/biosoc.2014.40
中图分类号
R318 [生物医学工程]; C [社会科学总论];
学科分类号
03 ; 0303 ; 0831 ;
摘要
The contemporary era is characterised by the development of knowledge economies in which scientific research and technical innovation are seen as the motor for growth and competitive advantage. Nowhere is this more apparent than in the biosciences, where the emerging bioeconomy is surrounded by high hopes, but remains an area with few working technologies entering routine use. These developments have focused scholarly attention on the performative role that sociotechnical expectations play in constituting new scientific and technological domains. However, relatively little is known about the role of expectations in the commercial development of new technologies, the commodification of knowledge and the creation of economic value. This article therefore seeks to address these questions by exploring the role of expectations in the creation of a new industrial sector based on the commercial development of neurotechnology in the United States. In particular, it will focus on the role of two types of 'promissory organisation' in the making of the neuroindustry, how different regimes of hope and promise have been constructed around distinct groups of companies, and the complex relationship between these regimes. In conclusion, some reflections will be made about the way in which high-technology industries, sociotechnical futures and new forms of promissory value are co-produced.
引用
收藏
页码:422 / 443
页数:22
相关论文
共 51 条
[11]   Strategic alliances and the rate of new product development: An empirical study of entrepreneurial biotechnology firms [J].
Deeds, DL ;
Hill, CWL .
JOURNAL OF BUSINESS VENTURING, 1996, 11 (01) :41-55
[12]   The price of innovation: new estimates of drug development costs [J].
DiMasi, JA ;
Hansen, RW ;
Grabowski, HG .
JOURNAL OF HEALTH ECONOMICS, 2003, 22 (02) :151-185
[13]  
Gompers P., 1999, VENTURE CAPITAL CYCL
[14]   The drugs don't work: Expectations and the shaping of pharmacogenetics [J].
Hedgecoe, A ;
Martin, P .
SOCIAL STUDIES OF SCIENCE, 2003, 33 (03) :327-364
[15]  
Helmreich Stefan., 2008, Science as Culture, V17, P463, DOI DOI 10.1080/09505430802519256
[16]  
Hilgartner S., 2007, Biosocieties, V2, P382, DOI [DOI 10.1017/S1745855207005819, 10.1017/s1745855207005819]
[17]   Public expectations of gene therapy - Scientific futures and their performative effects on scientific citizenship [J].
Horst, Maja .
SCIENCE TECHNOLOGY & HUMAN VALUES, 2007, 32 (02) :150-171
[18]  
Kaplan S, 2010, RES SOCIOL ORGAN-RES, V29, P107, DOI 10.1108/S0733-558X(2010)0000029013
[19]   Licensing as a commercialisation strategy for new technology-based firms [J].
Kollmer, H ;
Dowling, M .
RESEARCH POLICY, 2004, 33 (08) :1141-1151
[20]   VENTURE CAPITALISTS AND THE DECISION TO GO PUBLIC [J].
LERNER, J .
JOURNAL OF FINANCIAL ECONOMICS, 1994, 35 (03) :293-316